Oct 2026· Eurasian journal of applied biotechnology· pp. 19-26· 0 citations· 2 references
TL;DR
The combined use of ddPCR and NGS improves the accuracy of molecular characterization of mCRC and is essential for personalized therapy selection.
Abstract
Colorectal cancer (CRC) is characterized by significant molecular heterogeneity, with mutations in the KRAS and BRAF genes playing a key role in carcinogenesis and determining the effectiveness of anti-EGFR therapy. Data on the frequency of these mutations remain limited in the Kazakhstani population.
The aim of our study was to determine the frequency and spectrum of KRAS and BRAF mutations in primary tumors and metastatic lesions in patients with metastatic CRC using ddPCR and targeted sequencing.
The study included FFPE tumor tissue and liver metastasis samples from 30 patients. Screening for KRAS and BRAF mutations was performed using droplet digital PCR, and targeted NGS was used for validation and extended analysis of the mutational profile.
KRAS mutations were detected in 31.6% of primary tumors and 23.1% of metastases using targeted sequencing. The most common mutation was G12V, found in 21.1% of primary tumors and 15.4% of metastases. A greater diversity of KRAS variants was observed in primary tumors. BRAF mutations were detected significantly less frequently: V600G was the predominant mutation in primary tumors (5.3%), while V600E was found in metastases (15.4%).
The combined use of ddPCR and NGS improves the accuracy of molecular characterization of mCRC and is essential for personalized therapy selection.
Background: KRAS and BRAF mutations predict resistance to antibodies against the epidermal growth factor receptor (EGFR) in colorectal carcinoma (CRC), but Bangladeshi data are scarce. This study determined KRAS and BRAF mutation frequencies in resected CRC and their associations with clinicopathological features and t...
S. M. Kamrul Hasan, Mohammad Kamal, Most. Israt Jahan et al.· Journal of Netrokona Medical...· 0 citations
ABSTRACT Background: Colorectal cancer is a global health problem with high incidence and mortality rates, frequently diagnosed at metastatic stages. Mutations in the KRAS gene play a key role in colorectal cancer progression, significantly influencing treatment resistance and prognosis. Aims: This study investigated t...
Eduardo Toaza, Eva Valadares Soares, E. Cambruzzi· Arquivos brasileiros de ciru...· 0 citations
Introduction
. Metastatic colorectal cancer (mCRC) remains a leading cause of cancer-related mortality worldwide. BRAF mutations (predominantly V600E) occur in 5–10% of mCRC cases and are associated with an aggressive disease phenotype, poor response to conventional chemotherapy, and dismal prognosis. In the Russian...
A. S. Fattakhova, S. V. Cheporov, N. P. Shiryaev· Medical alphabet· 0 citations
The mutation frequency in cerebral metastases of colorectal cancer in a representative Russian cohort is described and the absence of a direct association between the studied markers and the clinico-morphological characteristics of intracranial lesions is indicated.
D. Khalafyan, A. Bekyashev, A. Stroganova et al.· Malignant tumours· 0 citations
Background KRAS, NRAS, and BRAF (RAS/RAF) genes mutations play a role in the pathogenesis of multiple myeloma (MM). We conducted this study to investigate whether RAS/RAF genes mutations have a prognostic value in patients with MM. Material and methods 117 newly diagnosed MM patients underwent the FISH technique to det...
P. Pham, Hoang Viet Nguyen, M. Vu· Leukemia Research Reports· 0 citations
Background:
The mutation of the KRAS proto-oncogene is frequently detected in various cancers, including hepatocellular carcinoma (HCC). This mutation often results in the failure of treatments based on tyrosine kinase receptor inhibitors. The study's objective was to investigate mutations of codon 12 and 13 of the...
D. Thorpe, Thiam Souleymane, Samba Abdourahmane et al.· International Journal of Gen...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.